CN106170300A - Cd19‑抗体药物偶联物的优化给药 - Google Patents

Cd19‑抗体药物偶联物的优化给药 Download PDF

Info

Publication number
CN106170300A
CN106170300A CN201580019099.2A CN201580019099A CN106170300A CN 106170300 A CN106170300 A CN 106170300A CN 201580019099 A CN201580019099 A CN 201580019099A CN 106170300 A CN106170300 A CN 106170300A
Authority
CN
China
Prior art keywords
cd19a
sgn
dose
weeks
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580019099.2A
Other languages
English (en)
Chinese (zh)
Inventor
B·赵
T·艾伯特森
T·韩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of CN106170300A publication Critical patent/CN106170300A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201580019099.2A 2014-04-08 2015-04-07 Cd19‑抗体药物偶联物的优化给药 Pending CN106170300A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461976790P 2014-04-08 2014-04-08
US61/976,790 2014-04-08
PCT/US2015/024732 WO2015157297A1 (en) 2014-04-08 2015-04-07 Optimal dosing of a cd19-antibody drug conjugate

Publications (1)

Publication Number Publication Date
CN106170300A true CN106170300A (zh) 2016-11-30

Family

ID=54288332

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580019099.2A Pending CN106170300A (zh) 2014-04-08 2015-04-07 Cd19‑抗体药物偶联物的优化给药

Country Status (12)

Country Link
US (1) US20170182178A1 (https=)
EP (1) EP3129052B1 (https=)
JP (1) JP2017512801A (https=)
KR (1) KR20160141727A (https=)
CN (1) CN106170300A (https=)
AU (1) AU2015244004A1 (https=)
CA (1) CA2941154A1 (https=)
EA (1) EA201692016A1 (https=)
IL (1) IL247526A0 (https=)
MX (1) MX2016012258A (https=)
SG (1) SG11201607133QA (https=)
WO (1) WO2015157297A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069584A (zh) * 2017-06-29 2018-12-21 成都华创生物技术有限公司 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法
CN111683971A (zh) * 2017-12-23 2020-09-18 宇越生医科技股份有限公司 医药重组受体组成物及方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3481868A1 (en) * 2016-07-08 2019-05-15 Genmab A/S New dosage regimens for antibody drug conjugates based on anti-axl antibodies
MX2019015042A (es) * 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938046A (zh) * 2003-11-06 2007-03-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
CN101903403A (zh) * 2007-10-19 2010-12-01 西雅图基因公司 Cd19结合剂及其应用
CN103119065A (zh) * 2010-06-15 2013-05-22 根马布股份公司 针对组织因子的人抗体药物缀合物
CN103561759A (zh) * 2010-10-22 2014-02-05 西雅图遗传学公司 以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714738B1 (en) * 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938046A (zh) * 2003-11-06 2007-03-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
CN101903403A (zh) * 2007-10-19 2010-12-01 西雅图基因公司 Cd19结合剂及其应用
CN103119065A (zh) * 2010-06-15 2013-05-22 根马布股份公司 针对组织因子的人抗体药物缀合物
CN103561759A (zh) * 2010-10-22 2014-02-05 西雅图遗传学公司 以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069584A (zh) * 2017-06-29 2018-12-21 成都华创生物技术有限公司 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法
WO2019000327A1 (zh) * 2017-06-29 2019-01-03 成都华创生物技术有限公司 一种trail类蛋白持续抑制肿瘤细胞生长的给药方法
CN111683971A (zh) * 2017-12-23 2020-09-18 宇越生医科技股份有限公司 医药重组受体组成物及方法

Also Published As

Publication number Publication date
KR20160141727A (ko) 2016-12-09
JP2017512801A (ja) 2017-05-25
WO2015157297A1 (en) 2015-10-15
MX2016012258A (es) 2017-01-06
EP3129052B1 (en) 2020-06-03
EP3129052A1 (en) 2017-02-15
IL247526A0 (en) 2016-11-30
CA2941154A1 (en) 2015-10-15
EP3129052A4 (en) 2017-11-15
EA201692016A1 (ru) 2017-01-30
SG11201607133QA (en) 2016-09-29
AU2015244004A1 (en) 2016-09-15
US20170182178A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
JP2020183413A (ja) Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法
Socinski et al. Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease
US7794713B2 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
CN112546217B (zh) 用于治疗肿瘤的抗b7-h1抗体
US10792370B2 (en) Antibody-drug conjugate
JP7145891B2 (ja) 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
JP2016509582A5 (https=)
JP2007537460A (ja) アルブミン結合蛋白質を標的として用いる治療法
TW201311274A (zh) 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法
AU2018358120A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2022064906A (ja) ｕＰＡＲＡＰを標的にする抗体薬物複合体
JP2021525735A (ja) 抗ｃｄ３７免疫コンジュゲート投薬レジメン
CN106170300A (zh) Cd19‑抗体药物偶联物的优化给药
US20250043023A1 (en) Targeting moiety-drug grafted immune cell compositions and methods of use
KR20200028950A (ko) 항-cd25 adc의 투여를 위한 투약량 체제
JP6722688B2 (ja) 医薬組成物、調製及びその使用
Tian et al. Bone-specific enhancement of antibody therapy for breast cancer metastasis to bone
JP7590083B2 (ja) 併用療法
JP6591665B2 (ja) Ｔ−ｄｍ１難治性がん患者のｓｙｄ９８５処置
JP2021533090A (ja) 併用療法
AU2005325227B2 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
AU2019450366B2 (en) Use of an RXR agonist in treating Her2+ cancers
US20200230254A1 (en) Combination therapy using a cd19-adc and rchp
WO2023108015A1 (en) Use of an rxr agonist in treating drug resistant her2+ cancers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161130